Clinical trial
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of Gemigliptin 50mg in Patients With Type 2 Diabetes Who Have Inadequate glycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
NCT03842267 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of Gemigliptin 50mg in Patients With Type 2 Diabetes Who Have Inadequate glycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
- Lead sponsor
- LG Chem
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 13, 2019
- Completion date
- November 30, 2022
- Enrollment
- 315 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.